Most Popular News Stories on OBR Daily
The ten most read articles fromOBR Daily in the past month, updated continually:
(USA Today) Feb 28, 2017 - Colon and rectal cancers have increased dramatically and steadily in millennials and Generation X adults in the United States over the past four decades, a study confirmed Tuesday.
(2017 Quality Care Symposium) Mar 3, 2017 - Four studies exploring key issues in providing high-quality patient care will be presented at the 2017 Quality Care Symposium, taking place March 3–4, at Rosen Shingle Creek in Orlando, FL. These notable abstracts examine and implement various approaches to improving the quality of treatment and care for patients with cancer.
(StreetInsider) Mar 20, 2017 - Results to date confirm that single injection of BL-8040 mobilizes sufficient amounts of cells required for allogeneic transplantation without need for G-CSF; top-line results expected by end of 2017.
(Medscape Medical News) Mar 9, 2017 - Although many people respond well to immunotherapy, some patients have cancers that appear to rapidly progress with treatment. Genomics could be the key to identifying these cases in advance.
(Xconomy San Francisco) Mar 2, 2017 - There may be a new standard of care coming for a large portion of women with breast cancer who have had surgery to remove their tumors.
(Reuters) Mar 6, 2017 - OncoCyte Corp, which is developing diagnostics in the fledgling field of liquid biopsies, said on Monday a 300-patient validation study of its blood test for early detection of lung cancer has confirmed the accuracy reported from a prior trial.
(New York Times) Mar 21, 2017 - A rare cancer first linked to breast implants in 2011 has now been associated with nine deaths, the Food and Drug Administration said Tuesday.
(New York Times) Mar 14, 2017 - The reputation of Roundup, whose active ingredient is the world’s most widely used weed killer, took a hit on Tuesday when a federal court unsealed documents raising questions about its safety and the research practices of its manufacturer, the chemical giant Monsanto.
(MedPage Today) March 3, 2017 - The Medicare Payment Advisory Committee (MedPAC) says that the way physicians are paid for administering drugs under Part B of the Medicare program should be changed, but not all committee members agree on how that change should occur.
(Seattle Times) Mar 1, 2017 - The Seattle biotech will permanently stop the “Rocket” trial of JCAR015 to treat acute lymphoblastic leukemia in adults, three months after it was put on hold following patient deaths.